Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

Arcaini, Luca; Vallisa, Daniele; Rattotti, Sara; Ferretti, Virginia Valeria; Ferreri, A.J.; Bernuzzi, Patrizia; Merli, Michele; Varettoni, Marzia; Chiappella, Annalisa; Ambrosetti, Achille; Tucci, Alessandra; Rusconi, Chiara; Visco, Carlo; Spina, Michele; Cabras, Giuseppina; Luminari, Stefano; Tucci, Marco; Musto, Pellegrino; Ladetto, Marco; Merli, Francesco; Stelitano, Caterina; D’Arco, Alfonso Maria; Rigacci, Luigi; Levis, Alessandro; Rossi, Davide; Spedini, Pierangelo; Mancuso, Salvatrice; Marino, Dario; Bruno, Raffaele; Baldini, Luca; Pulsoni, Alessandro

doi:10.1093/annonc/mdu166

Cited by 154 publications

(175 citation statements)

References 14 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…Our results are also in line with those recently reported by Arcaini et al [16] with a 78% 5-year OS among patients with HCV associated low-grade lymphomas. Also in line with Arcaini, our data show that AT is associated with improved survival in this MZL emphasizing that AT is the cornerstone of treatment of HCV-related MZL.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

et al. 2014

View full text Add to dashboard Cite

on behalf of the ANRS HC-13 Lympho-C Study Group Hepatitis C virus (HCV) infection increases the risk of B-cell non-Hodgkin lymphomas (B-NHL). Antiviral treatment (AT) can induce hematological responses in patients with marginal zone lymphomas (MZL). The ANRS HC-13 Lympho-C study aimed at a better understanding of the impact of AT on HCV associated B-NHL. This multicentric study enrolled 116 HCV-positive patients with B-NHL between 2006 and 2012. Cytological and histological samples were collected for centralized review. At lymphoma diagnosis, median age was 61 years and gender ratio M/F was 1. Cytohistological distribution was marginal zone lymphoma (MZL) n 5 45 (39%), diffuse large B-cell lymphoma (DLBCL) n 5 45 (39%), and other types n 5 26 (22%). MZL patients had more frequent detection of rheumatoid factor (68% vs. 35%; P 5 0.001) and more frequently mixed cryoglobulinemia (74% vs. 44%; P 5 0.021) than patients with DLBCL. Among patients receiving AT, a sustained virologic response was achieved in 23 of 38 (61%) patients with MZL and in 9 of 17 (53%) with DLBCL (P 5 0.42). Three-year overall survival (OS) and progression-free survival were 78% 95%CI and 64% , respectively, without difference between cytohistological groups. Outcome analysis showed a favorable association between OS and AT in all patients (P 5 0.05) and in the subgroup of MZL patients only (P 5 0.04). Our data support that AT improves the outcomes of HCV-associated NHLs. The impact of new AT regimen with protease inhibitor needs to be investigated in this setting. [clinicalTrials.gov Identification number NCT01545544]Am.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Arcaini et al [16] recently reported a favorable association between AT and overall survival (OS) in indolent B-NHL in the context of a retrospective study. There is no data assessing the role of AT in the management of patients with DLBCL.…”

Section: Introductionmentioning

confidence: 99%

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…105 The first experience was reported by Hermine et al 9 in 9 SMZL patients with HCV infection treated with interferon (IFN): 7 patients obtained a complete hematologic remission and HCV-RNA negativity. In a cohort of 704 consecutive HCV-positive patients with indolent NHL (137 patients had SMZL) reported by FIL, 36 SMZL patients were treated with IFN-based antiviral treatment as a first-line approach, and 65% showed a response.…”

Section: Hcv Infection and Antiviral Treatmentmentioning

confidence: 99%

Splenic marginal zone lymphoma: from genetics to management

Arcaini

Rossi

Paulli

2016

Blood

138

132

View full text Add to dashboard Cite

Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy involving the spleen, bone marrow, and frequently the blood. SMZL lymphomagenesis involves antigen and/or superantigen stimulation and molecular deregulation of genes (NOTCH2 and KLF2) involved in the physiological differentiation of spleen marginal zone B cells. Diagnosis requires either spleen histology or, alternatively, the documentation of a typical cell morphology and immunophenotype on blood cells coupled with the detection of intrasinusoidal infiltration by CD20+ cells in the bone marrow. Among B-cell tumors, deletion of 7q and NOTCH2 mutations are almost specific lesions of SMZL, thus representing promising diagnostic biomarkers of this lymphoma. Although the majority of SMZLs show an indolent course with a median survival of approximately 10 years, nearly 30% of patients experience a poor outcome. No randomized trials are reported for SMZL, and few prospective trials are available. A watch-and-wait approach is advisable for asymptomatic patients. Treatment options for symptomatic patients ranges from splenectomy to rituximab alone or combined with chemotherapy. In some geographic areas, a subset of patients with SMZL associates with hepatitis C virus infection, prompting virus eradication as an effective lymphoma treatment. It would be worthwhile to explore deregulated cellular programs of SMZL as therapeutic targets in the future; improved clinical and biological prognostication will be essential for identifying patients who may benefit from novel approaches.

show abstract

“…3,4 Furthermore, eradication of the chronic HCV infection has been correlated with regression of certain NHLs. 5 However, studies of patients with HCV infection and specific histological types of NHL and Hodgkin lymphoma (HL) are limited. We thus sought to determine the prevalence of HCV seropositivity in patients with different subtypes of NHL and HL and its association with these subtypes.…”

mentioning

confidence: 99%

Prevalence and association of hepatitis C virus infection with different types of lymphoma

Iqbal

Mahale

Turturro

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

Cited by 154 publications

References 14 publications

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

Splenic marginal zone lymphoma: from genetics to management

Prevalence and association of hepatitis C virus infection with different types of lymphoma

Contact Info

Product

Resources

About